JP2022506719A5 - - Google Patents
Info
- Publication number
- JP2022506719A5 JP2022506719A5 JP2021524282A JP2021524282A JP2022506719A5 JP 2022506719 A5 JP2022506719 A5 JP 2022506719A5 JP 2021524282 A JP2021524282 A JP 2021524282A JP 2021524282 A JP2021524282 A JP 2021524282A JP 2022506719 A5 JP2022506719 A5 JP 2022506719A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- occupied
- cdr
- antibody according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025003312A JP2025063136A (ja) | 2018-11-08 | 2025-01-09 | タウ認識抗体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| USPCT/US2018/059895 | 2018-11-08 | ||
| PCT/US2018/059895 WO2020096608A1 (en) | 2018-11-08 | 2018-11-08 | Antibodies recognizing tau |
| US201862758421P | 2018-11-09 | 2018-11-09 | |
| US62/758,421 | 2018-11-09 | ||
| PCT/US2019/060616 WO2020097561A1 (en) | 2018-11-08 | 2019-11-08 | Antibodies recognizing tau |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025003312A Division JP2025063136A (ja) | 2018-11-08 | 2025-01-09 | タウ認識抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022506719A JP2022506719A (ja) | 2022-01-17 |
| JP2022506719A5 true JP2022506719A5 (https=) | 2022-11-15 |
| JP7623699B2 JP7623699B2 (ja) | 2025-01-29 |
Family
ID=70610738
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021524282A Active JP7623699B2 (ja) | 2018-11-08 | 2019-11-08 | タウ認識抗体 |
| JP2025003312A Pending JP2025063136A (ja) | 2018-11-08 | 2025-01-09 | タウ認識抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025003312A Pending JP2025063136A (ja) | 2018-11-08 | 2025-01-09 | タウ認識抗体 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20220153821A1 (https=) |
| EP (1) | EP3877410A4 (https=) |
| JP (2) | JP7623699B2 (https=) |
| KR (1) | KR20210090184A (https=) |
| CN (2) | CN113454112B (https=) |
| BR (1) | BR112021008624A2 (https=) |
| CL (1) | CL2021001158A1 (https=) |
| CO (1) | CO2021007370A2 (https=) |
| CU (1) | CU24781B1 (https=) |
| IL (1) | IL283049A (https=) |
| JO (1) | JOP20210098A1 (https=) |
| MX (1) | MX2021005411A (https=) |
| PE (1) | PE20211777A1 (https=) |
| PH (1) | PH12021551048A1 (https=) |
| SG (1) | SG11202104549TA (https=) |
| UA (1) | UA129124C2 (https=) |
| WO (1) | WO2020097561A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10501531B2 (en) | 2013-03-13 | 2019-12-10 | Prothena Biosciences Limited | Tau immunotherapy |
| PT3452507T (pt) | 2016-05-02 | 2022-12-20 | Prothena Biosciences Ltd | Imunoterapia anti-tau |
| MX2018013386A (es) | 2016-05-02 | 2019-02-28 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau. |
| MY198194A (en) | 2016-05-02 | 2023-08-09 | Prothena Biosciences Ltd | Antibodies Recognizing Tau |
| KR102784294B1 (ko) | 2017-05-02 | 2025-03-19 | 프로테나 바이오사이언시즈 리미티드 | 타우 인식 항체 |
| CU24781B1 (es) * | 2018-11-08 | 2026-02-09 | Prothena Biosciences Ltd | Anticuerpos humanizados que reconocen tau |
| JP7630834B2 (ja) | 2019-03-03 | 2025-02-18 | プロセナ バイオサイエンシーズ リミテッド | タウ認識抗体 |
| US20250034559A1 (en) | 2021-11-17 | 2025-01-30 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| KR20250069606A (ko) | 2022-09-15 | 2025-05-19 | 보이저 테라퓨틱스, 인크. | 타우 결합 화합물 |
| CN115724967A (zh) * | 2022-09-21 | 2023-03-03 | 天津鸿宇泰生物科技有限公司 | 一种识别Tau蛋白N端区域的单克隆抗体及其应用 |
| CN116925217B (zh) * | 2023-09-14 | 2024-03-08 | 北京凯祥弘康生物科技有限公司 | 针对Tau蛋白的抗体 |
| WO2025122634A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5208036A (en) | 1985-01-07 | 1993-05-04 | Syntex (U.S.A.) Inc. | N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| EP0832981A1 (en) | 1987-02-17 | 1998-04-01 | Pharming B.V. | DNA sequences to target proteins to the mammary gland for efficient secretion |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| US5194594A (en) | 1990-09-07 | 1993-03-16 | Techniclone, Inc. | Modified antibodies |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
| US5674703A (en) | 1992-12-02 | 1997-10-07 | Woo; Savio L. C. | Episomal vector systems and related methods |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5505947A (en) | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
| US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| US7153510B1 (en) | 1995-05-04 | 2006-12-26 | Yale University | Recombinant vesiculoviruses and their uses |
| DE19539493A1 (de) | 1995-10-24 | 1997-04-30 | Thomae Gmbh Dr K | Starker homologer Promotor aus Hamster |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
| US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
| US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| NZ513144A (en) | 1999-02-05 | 2003-05-30 | Samsung Electronics Co Ltd | Image texture retrieving method and apparatus thereof |
| PE20020574A1 (es) | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| EP1470146B8 (en) | 2001-12-28 | 2007-09-12 | Amgen Fremont Inc. | Antibodies against the muc18 antigen |
| JP4344325B2 (ja) | 2002-11-29 | 2009-10-14 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 新規なネオマイシンホスホトランスフェラーゼ遺伝子及び高生産組換え細胞の選抜方法 |
| DE10338531A1 (de) | 2003-08-19 | 2005-04-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Reklonierung von Produktionszellen |
| CA2578400C (en) | 2004-11-10 | 2014-01-14 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of flow-cytometric analysis to optimize cell banking strategies for cho cells |
| US20080124760A1 (en) | 2006-07-26 | 2008-05-29 | Barbara Enenkel | Regulatory Nucleic Acid Elements |
| PT2099823E (pt) | 2006-12-01 | 2014-12-22 | Seattle Genetics Inc | Agentes de ligação ao alvo variantes e suas utilizações |
| PL2583978T3 (pl) | 2007-02-23 | 2016-07-29 | Prothena Biosciences Ltd Co | Profilaktyka i leczenie chorób synukleinopatycznych i amyloidogennych |
| NZ580043A (en) | 2007-03-02 | 2012-04-27 | Boehringer Ingelheim Pharma | Improvement of protein production through increased expression of mutated start domain protein cert |
| EP2031064A1 (de) | 2007-08-29 | 2009-03-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verfahren zur Steigerung von Proteintitern |
| CA2813493C (en) * | 2010-10-11 | 2019-07-09 | University Of Zurich | Human anti-tau antibodies |
| ME03008B (me) * | 2011-09-19 | 2018-10-20 | Axon Neuroscience Se | Terapija na osnovu proteina i dijagnoza patologije u којој posreduje tau u alcнajмerovoj bolesti |
| RU2644242C2 (ru) * | 2012-04-05 | 2018-02-08 | Ац Иммуне С.А. | Гуманизированное тау-антитело |
| CA2896066C (en) * | 2012-12-21 | 2022-07-12 | Biogen Ma Inc. | Human anti-tau antibodies |
| CN107428820B (zh) * | 2014-11-19 | 2022-03-22 | 阿克松神经系统科学公司 | 在阿尔茨海默氏病中的人源化tau抗体 |
| NZ775762A (en) * | 2015-06-05 | 2025-02-28 | Genentech Inc | Anti-tau antibodies and methods of use |
| US10639383B2 (en) | 2015-11-23 | 2020-05-05 | Sangamo Therapeutics, Inc. | Methods and compositions for engineering immunity |
| MY198194A (en) * | 2016-05-02 | 2023-08-09 | Prothena Biosciences Ltd | Antibodies Recognizing Tau |
| CA3030754C (en) * | 2016-07-20 | 2022-04-26 | Anahit Ghochikyan | Humanized anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies |
| CU24781B1 (es) * | 2018-11-08 | 2026-02-09 | Prothena Biosciences Ltd | Anticuerpos humanizados que reconocen tau |
| JP7630834B2 (ja) * | 2019-03-03 | 2025-02-18 | プロセナ バイオサイエンシーズ リミテッド | タウ認識抗体 |
-
2019
- 2019-11-08 CU CU2021000039A patent/CU24781B1/es unknown
- 2019-11-08 MX MX2021005411A patent/MX2021005411A/es unknown
- 2019-11-08 SG SG11202104549TA patent/SG11202104549TA/en unknown
- 2019-11-08 WO PCT/US2019/060616 patent/WO2020097561A1/en not_active Ceased
- 2019-11-08 PE PE2021000683A patent/PE20211777A1/es unknown
- 2019-11-08 UA UAA202103099A patent/UA129124C2/uk unknown
- 2019-11-08 US US17/291,986 patent/US20220153821A1/en active Pending
- 2019-11-08 KR KR1020217014397A patent/KR20210090184A/ko active Pending
- 2019-11-08 BR BR112021008624-2A patent/BR112021008624A2/pt unknown
- 2019-11-08 EP EP19881978.1A patent/EP3877410A4/en active Pending
- 2019-11-08 CN CN201980073684.9A patent/CN113454112B/zh active Active
- 2019-11-08 CN CN202411549401.2A patent/CN119409813A/zh active Pending
- 2019-11-08 JP JP2021524282A patent/JP7623699B2/ja active Active
-
2021
- 2021-05-03 CL CL2021001158A patent/CL2021001158A1/es unknown
- 2021-05-04 JO JOP/2021/0098A patent/JOP20210098A1/ar unknown
- 2021-05-06 PH PH12021551048A patent/PH12021551048A1/en unknown
- 2021-05-09 IL IL283049A patent/IL283049A/en unknown
- 2021-06-04 CO CONC2021/0007370A patent/CO2021007370A2/es unknown
-
2025
- 2025-01-09 JP JP2025003312A patent/JP2025063136A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022506719A5 (https=) | ||
| IL262726B1 (en) | Antibodies recognizing tau | |
| JP2025029046A5 (https=) | ||
| KR102482710B1 (ko) | 항-pd-1 항체, 이의 생산 방법 및 사용 방법 | |
| JP2022520672A5 (https=) | ||
| JP2020078319A (ja) | Ｃｄ２６９（ｂｃｍａ）に対する抗体 | |
| JP2018510617A5 (https=) | ||
| JP2016512551A5 (https=) | ||
| JP2019525724A5 (https=) | ||
| JP6666257B2 (ja) | プロアポトーシス活性を有するｇｄ２−ｏ−アセチル化ガングリオシドに対する抗体 | |
| JP2022524588A5 (https=) | ||
| JP2020513791A5 (https=) | ||
| JP2019525728A5 (https=) | ||
| JP2010532764A5 (https=) | ||
| US20160207996A1 (en) | Antibodies to complex targets | |
| JP2013056885A5 (https=) | ||
| JP2012515746A (ja) | 抗ｃｄ１６０モノクローナル抗体及びその使用 | |
| JP2020536532A5 (https=) | ||
| JP2012525829A5 (https=) | ||
| JP2010524435A5 (https=) | ||
| RU2019140602A (ru) | АНТИ-GARP-TGF-β-АНТИТЕЛА | |
| JP2018509889A5 (https=) | ||
| JP2018506277A5 (https=) | ||
| JP2022506719A (ja) | タウ認識抗体 | |
| JP2021094022A5 (https=) |